Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dystonia - Pipeline Review, H2 2016, provides an overview of the Dystonia (Central Nervous System) pipeline landscape.
Dystonia is a movement disorder that causes the muscles to contract and spasm involuntarily. The movements may be painful, and some individuals with dystonia may have a tremor or other neurologic features. Symptoms include involuntary muscle contractions that cause repetitive movements or distorted postures, stress, fatigue or anxiety and speech difficulties. Treatment includes anticholinergic and benzodiazepines.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dystonia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dystonia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dystonia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dystonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Dystonia.
Dystonia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dystonia (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Dystonia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dystonia (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dystonia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dystonia (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dystonia (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dystonia (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Report Scope: This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development...
Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020
According to the recently published report ’Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020’; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 12 molecules. Out of...
Narcolepsy - Pipeline Review, H2 2020
This latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.
Narcolepsy is a sleep disorder that causes excessive...
The current practice of medical education and methods of performing surgery and therapy suffer from limitations such as scarcity of subjects to practice on, suboptimal surgical precision, and therapy-related issues including medication misuse and ineffectiveness of the drugs to treat the conditions. Moreover, the outbreak of COVID-19 pandemic...
Giving support: Funding increases should help the industry recover from current-year disruption Abstract Learning Disability, Mental Health & Substance Abuse Facilities in the UK Operators in this industry provide residential care for people with learning disabilities, mental illness or substance abuse...
Aiding care: Emergency funding to counteract the effects of COVID-19 is expected to support industry revenue Abstract Domiciliary Care in the UK Companies operating in the Domiciliary Care industry provide intensive, at-home nursing care to patients. Residential nursing care activities are excluded...
400 pages •
By The Business Research Company
• Feb 2021
Major companies in the residential substance abuse and mental health facilities market include National Health Service; Universal Health Services; Acadia Healthcare Company Inc; Kindred Healthcare Inc. and Genesis Healthcare. The global residential substance abuse and mental health facilities market is expected to grow from $73.73 billion...
Report Scope: This report provides an overview of the global market for exoskeletons and analyzes market trends.Using 2019 as the base year, the report provides estimated market data for the forecast period 2020 through 2025. Revenue forecasts for this period are segmented based on mobility, type, power, segment...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.